Pharma News

Sea cucumbers are the ocean's janitors, cleaning the seabed and recycling nutrients back into the water. But this humble marine invertebrate could also hold the key to stopping the spread of cancer.

Bharat Biotech International Limited (BBIL) has entered into a licensing agreement with GSK plc to take over the development of altSonflex1‑2‑3, GSK’s promising Shigella vaccine candidate.

Novartis announced promising results from its Phase IIIB APPULSE-PNH study, evaluating the twice-daily oral monotherapy Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria

NVIDIA announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases. The work supports Novo Nordisk’s agreement with DCAI to use the Gefion sovereign AI supercomputer.

Pharmazz, Inc. a late-stage biopharmaceutical company developing innovative therapies for unmet medical needs in critical care and neurology, has announced a 25 million USD equity investment from Sun Pharmaceutical Industries Limited

Telix Pharmaceuticals Limited announces that its next-generation PSMA-PET imaging1 agent for prostate cancer, Gozellix (kit for the preparation of gallium-68 , is now commercially available nationally in the United States (U.S.).

Biocon Foundation, the Corporate Social Responsibility arm of Biocon Group in collaboration with The Bengaluru Science and Technology (BeST) Cluster, and National Centre for Biological Sciences (NCBS) today announced the launch of first-of-its-kind program BioWISE – Women in STEM Empowered, aimed at disadvantaged science students from tier 2 and 3 universities across Karnataka, to build a career in life sciences.

Zydus Lifesciences has received the Establishment Inspection Report from the United States Food and Drug Administration for its Active Pharmaceutical Ingredient manufacturing facility located at Dabhasa, near Vadodara, Gujarat.

A new study published in the journal Diabetes, Obesity and Metabolism has found that sodium-glucose co-transporter-2 (SGLT2) inhibitors are associated with a reduced incidence of atrial fibrillation in patients with type 2 diabetes mellitus.